The prognosis of patients with epidermal growth factor receptor (EGFR)mutation-positive lung cancer has improved significantly since the advent of EGFR tyrosine kinase inhibitors (EGFR-TKIs). We aimed to investigate the relationship between patient characteristics,EGFRgenotype, therapeutic agents, and the...
[5] GELATTI A C Z, DRILON A, SANTINI F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung ...
参考文献: Xie, Xiaohong et al. “Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.” Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 26,2...
[7] Moon Y, Park JK, Lee KY, Kim ES. Prognosis after wedge resection in patients with 8th edition TNM stage IA1 and IA2 non-small cell lung cancer. J Thorac Dis. 2019;11(6):2361-2372. doi: 10.21037/jtd...
employing EGFR inhibitors as potential therapeutic agents to improve the otherwise dismal prognosis of patients with pulmonary choriocarcinoma. The present case underscores the importance of EGFR screening even in pulmonary choriocarcinoma, as is the case with conventional non-small cell lung carcinomas. ...
医学评论英文版原文:Kanemura H, Takeda M, Nakagawa K. Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy? Transl Lung Cancer Res 2020;9(4):1617-1622. doi: 10.21037/tlcr-20-707 ...
“The prognosis for these patients is unfavorable – with overall survival rates much lower than seen in non-small cell lung cancer where more commonEGFRmutations are present - and is similar to what we see with wild-type lung cancer, prior to the advent of the new agents,” said Alexander...
12. Zhang S, Zhu L, Xia B, Chen E, Zhao Q, Zhang X, et al. (2018) Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor ...
[11]Wespiser M, Swalduz A, Pérol M. Treatment sequences in EGFR mutant advanced NSCLC. Lung Cancer. 2024 Aug;194:107895. [12]Lan B, Zhao N, Du K, Leng B. Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant N...
[5].Lee JK, Shin JY, Kim S, et al. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an ...